Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Subcutaneous and Oral Doses of GLPG0187 in Healthy Subjects.

Trial Profile

Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending Subcutaneous and Oral Doses of GLPG0187 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs GLPG 0187; GLPG 0187
  • Indications Breast cancer; Cancer metastases; Prostate cancer
  • Focus Adverse reactions; Biomarker
  • Sponsors Galapagos NV
  • Most Recent Events

    • 19 Jan 2010 Status changed from active, no longer recruiting to completed as reported in a Galapagos NV media release.
    • 19 Jan 2010 Favourable tolerability results have been reported in a Galapagos NV media release.
    • 03 Oct 2009 Planned end date changed from 1 Oct 2009 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top